Coronary heart disease: At the interface of molecular genetics and preventive medicine

American Journal of Preventive Medicine

Volumn 16, Issue 2, 1999, Pages 122-133

  Ellsworth, Darrell L ^a   Sholinsky, Phyliss ^a   Jaquish, Cashell ^a   Fabsitz, Richard R ^a   Manolio, Teri A ^a  

^a Div Epidemiol Clin Applic   (United States)

Author keywords

Cardiovascular diseases; Chemical and pharmacologic phenomena; Coronary disease; Pharmacogenetics; Polymorphism (genetics); Risk factors

Indexed keywords

ARTICLE; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; EPISTASIS; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MOLECULAR GENETICS; PREVENTIVE MEDICINE; PUBLIC HEALTH; SMOKING CESSATION;

CORONARY DISEASE; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENETICS, MEDICAL; HUMANS; LIFE STYLE; MOLECULAR BIOLOGY; MUTATION; PREVENTIVE MEDICINE; PRIMARY PREVENTION; RISK FACTORS; VARIATION (GENETICS);

EID: 0032987566     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(98)00138-X     Document Type: Article

References (87)

1. Report of the task force on research in epidemiology and prevention of cardiovascular diseases. National Institutes of Health. August. 1994.
2. Wilson P.W.F. Established risk factors and coronary artery disease the Framingham study . Am J Hypertens. 7:1994;7S-12S.
3. Perkins K.A. Relation between family history of coronary artery disease and coronary risk variables. Am J Cardiol. 63:1989;1539.
4. Goldstein J.L., Brown M.S. Familial hypercholesterolemia. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic basis of inherited disease. 1989;1215-1250 McGraw-Hill, Inc, New York.
5. Kang S.-S., Wong P.W.K., Malinow M.R. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 12:1992;279-298.
6. Bild D.E., Williams R.R., Brewer H.B., Herd J.A., Pearson T.A., Stein E. Identification and management of heterozygous familial hypercholesterolemia summary and recommendations from an NHLBI workshop . Am J Cardiol. 72:1993;1D-5D.
7. Sing C.F., Haviland M.B., Reilly S.L. Genetic architecture of common multifactorial diseases. Chadwick D., Cardew G. Variation in the human genome. 1996;211-232 John Wiley and Sons, Chichester, England.
8. Humphries S.E. DNA polymorphisms of the apolipoprotein genes-their use in the investigation of the genetic component of hyperlipidaemia and atherosclerosis. Atherosclerosis. 72:1988;89-108.
9. Jeunemaître X., Soubrier F., Kotelevtsev Y.V., et al. Molecular basis of human hypertension role of angiotensinogen . Cell. 71:1992;169-180.
10. Zerba K.E., Ferrell R.E., Sing C.F. Genotype-environment interaction apolipoprotein E (apoE) gene effects and age as an index of time and spatial context in the human . Genetics. 143:1996;463-478.
11. Reilly S.L., Ferrell R.E., Sing C.F. The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, MN. III. Correlations and covariances. Am J Hum Genet. 55:1994;1001-1018.
12. Ueland P.M., Refsum H. Plasma homocysteine, a risk factor for vascular disease plasma levels in health, disease, and drug therapy . J Lab Clin Med. 114:1989;473-501.
13. Linder M.W., Prough R.A., Valdes R. Jr. Pharmacogenetics a laboratory tool for optimizing therapeutic efficiency . Clin Chem. 43:1997;254-266.
14. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. In: Born GVR, Schwartz CJ, editors. New horizons in coronary heart disease. London, UK: Science Press Ltd., 1993;5.1-5.21.
15. Zannis V.I., Breslow J.L. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry. 20:1981;1033-1041.
16. Boerwinkle E., Hixson J.E. Genes and normal lipid variation. Curr Opin Lipidol. 1:1990;151-159.
17. Boerwinkle E., Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet. 42:1988;104-112.
18. Hixson J.E. Pathobiological Determinants of Atherosclerosis in Youth Research Group. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Arterioscler Thromb. 11:1991;1237-1244.
19. de Andrade M., Thandi I., Brown S., Gotto A. Jr, Patsch W., Boerwinkle E. Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. Am J Hum Genet. 56:1995;1379-1390.
20. Nieminen M.S., Mattila K.J., Aalto-Setälä K., et al. Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease. Arterioscler Thromb. 12:1992;58-69.
21. Wilson P.W.F., Schaefer E.J., Larson M.G., Ordovas J.M. Apolipoprotein E alleles and risk of coronary disease. Arterioscler Thromb Vasc Biol. 16:1996;1250-1255.
22. Carretero O.A., Scicli A.G. The kallikrein-kinin system as a regulator of cardiovascular and renal function. Laragh J.H., Brenner B.M. Hypertension: Pathophysiology, diagnosis, and management. 1995;983-999 Raven Press, Ltd, New York.
23. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 86:1990;1343-1346.
24. Villard E., Tiret L., Visvikis S., Rakotovao R., Cambien F., Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet. 58:1996;1268-1278.
25. Singer D.R.J., Missouris C.G., Jeffery S. Angiotensin-converting enzyme gene polymorphism what to do about all the confusion? Circulation. 94:1996;236-239.
26. Butler R., Morris A.D., Struthers A.D. Angiotensin-converting enzyme gene polymorphism and cardiovascular disease. Clin Sci. 93:1997;391-400.
27. Samani N.J., Thompson J.R., O'Toole L., Channer K., Woods K.L. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 94:1996;708-712.
28. Rosenblatt D.S. Inherited disorders of folate transport and metabolism. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic and molecular bases of inherited disease. 1995;3111-3128 McGraw-Hill, Inc, New York.
29. TM. Baltimore, MD. Johns Hopkins University. MIM Number 236200. Last edited 12 January 1998. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim.
30. D'Angelo A., Selhub J. Homocysteine and thrombotic disease. Blood. 90:1997;1-11.
31. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 98:1996;5-7.
32. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 274:1995;1049-1057.
33. 6 concentrations risk factors for stroke, peripheral vascular disease, and coronary artery disease . Circulation. 97:1998;437-443.
34. Kuller L.H., Evans R.W. Homocysteine, vitamins, and cardiovascular disease (editorial). Circulation. 98:1998;196-199.
35. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease a common mutation in methylenetetrahydrofolate reductase . Nat Genet. 10:1995;111-113.
36. Motulsky A.G. Nutritional ecogenetics homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid . Am J Hum Genet. 58:1996;17-20.
37. Morita H., Taguchi J., Kurihara H., et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 95:1997;2032-2036.
38. Kluijtmans L.A., Kastelein J.J., Lindemans J., et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 96:1997;2573-2577.
39. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:1993;971-983.
40. Kerem B., Rommens J.M., Buchanan J.A., et al. Identification of the cystic fibrosis gene genetic analysis . Science. 245:1989;1073-1080.
41. Hegele R.A. Gene-environment interactions in atherosclerosis. Mol Cell Biochem. 113:1992;177-186.
42. Bonnardeaux A., Davies E., Jeunemaître X., et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension. 24:1994;63-69.
43. Tiret L., Bonnardeaux A., Poirier O., et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet. 344:1994;910-913.
44. Reilly S.L., Ferrell R.E., Kottke B.A., Sing C.F. The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, Minnesota. II. Regression relationships with concomitants. Am J Hum Genet. 51:1992;1311-1324.
45. Jarvik G.P., Goode E.L., Austin M.A., et al. Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males a longitudinal analysis . Am J Hum Genet. 61:1997;171-181.
46. Xhignesse M., Lussier-Cacan S., Sing C.F., Kessling A.M., Davignon J. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler Thromb. 11:1991;1100-1110.
47. Kaprio J., Ferrell R.E., Kottke B.A., Kamboh M.I., Sing C.F. Effects of polymorphisms in apolipoproteins E, A-IV, and H on quantitative traits related to risk for cardiovascular disease. Arterioscler Thromb. 11:1991;1330-1348.
48. Gillum R.F. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol. 23:1994;1273-1277.
49. Barley J., Carter N.D., Kennedy Cruickshank J., et al. Renin and atrial natriuretic peptide restriction fragment length polymorphisms association with ethnicity and blood pressure . J Hypertens. 9:1991;993-996.
50. Bloem L.J., Manatunga A.K., Boatright E., et al. Relation of race and a polymorphism in the angiotensin I-converting enzyme gene to enzyme levels (abstract). Hypertension. 22:1993;407.
51. Rotimi C.N., Cooper R.S., Ward R.H., et al. The role of the angiotensinogen gene in human hypertension absence of an association among African Americans (abstract) . Genet Epidemiol. 10:1993;339-340.
52. Jacques P.F., Bostom A.G., Williams R.R., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7-9.
53. Nygård O., Vollset S.E., Refsum H., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 274:1995;1526-1533.
54. Brattstrom L., Lindgren A., Israelsson B., Andersson A., Hultberg B. Homocysteine and cysteine determinants of plasma levels in middle-aged and elderly subjects . J Intern Med. 236:1994;633-641.
55. Graham I.M., Daly L.E., Refsum H.M., et al. Plasma homocysteine as a risk factor for vascular disease the European Concerted Action Project . JAMA. 277:1997;1775-1781.
56. Lussier-Cacan S., Xhignesse M., Piolot A., Selhub J., Davignon J., Genest J. Jr. Plasma total homocysteine in healthy subjects sex-specific relation with biological traits . Am J Clin Nutr. 64:1996;587-593.
57. Tucker K.L., Selhub J., Wilson P.W., Rosenberg I.H. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. J Nutr. 126:1996;3025-3031.
58. Omenn G.S., Beresford S.A.A., Motulsky A.G. Preventing coronary heart disease B vitamins and homocysteine (Editorial) . Circulation. 97:1998;421-424.
59. Arcavi L., Benowitz N.L. Clinical significance of genetic influences on cardiovascular drug metabolism. Cardiovasc Drugs Ther. 7:1993;311-324.
60. Nelson D.R., Koymans L., Kamataki T., et al. P450 superfamily update on new sequences, gene mapping, accession numbers and nomenclature . Pharmacogenetics. 6:1996;1-42.
61. Gonzalez F.J., Skoda R.C., Kimura S., et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 331:1988;442-446.
62. Saxena R., Shaw G.L., Relling M.V., et al. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet. 3:1994;923-926.
63. Akullu E., Persson I., Bertilsson L., Johansson I., Rodrigues F., Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 278:1996;441-446.
64. Ward S.A., Walle T., Walle U.K., Wilkinson G.R., Branch R.A. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther. 45:1989;72-79.
65. Eichelbaum M., Gross A.S. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther. 46:1990;377-394.
66. Tam Y.K. Individual variation in first-pass metabolism. Clin Pharmacokinet. 25:1993;300-328.
67. Walter-Sack I., Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet. 31:1996;47-64.
68. Carmena R., Roederer G., Mailloux H., Lussier-Cacan S., Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism. 42:1993;895-901.
69. Ordovas J.M., Lopez-Miranda J., Perez-Jimenez F., et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis. 113:1995;157-166.
70. Nestruck A.C., Bouthillier D., Sing C.F., Davignon J. Apolipoprotein E polymorphism and plasma cholesterol response to probucol. Metabolism. 36:1987;743-747.
71. Wood A.J.J., Zhou H.H. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet. 20:1991;350-373.
72. Evans W.E., Relling M.V., Rahman A., McLeod H.L., Scott E.P., Lin J.-S. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in Black Americans. J Clin Invest. 91:1993;2150-2154.
73. 2max in the sedentary state the HERITAGE family study . Med Sci Sports Exerc. 30:1998;252-258.
74. 2max in the HERITAGE family study. Med Sci Sports Exerc. 29:1997;1311-1317.
75. Malcom G.T., Oalmann M.C., Strong J.P. Risk factors for atherosclerosis in young subjects: the PDAY study. Pathobiological Determinants of Atherosclerosis in Youth. Ann NY Acad Sci. 817:1997;179-188.
76. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the trials of hypertension prevention, phase I. JAMA. 267:1992;1213-1220.
77. Grossman M., Raper S.E., Kozarsky K., et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet. 6:1994;335-341.
78. Takeshita S., Tsurumi Y., Couffinahl T., et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest. 75:1996;487-501.
79. Feldman L.J., Isner J.M. Gene therapy for the vulnerable plaque. J Am Coll Cardiol. 26:1995;826-835.
80. Lifton R.P. Molecular genetics of human blood pressure variation. Science. 272:1996;676-680.
81. Institute of Medicine. Dietary reference intakes: folate, other B vitamins, and choline. Washington, DC: National Academy Press, 1998;8-1-8-47.
82. McKinnon W.C., Baty B.J., Bennett R.L., et al. Predisposition genetic testing for late-onset disorders in adults. A position paper of the National Society of Genetic Counselors. JAMA. 278:1997;1217-1220.
83. Bondy M., Mastromarino C. Ethical issues of genetic testing and their implications in epidemiologic studies. Ann Epidemiol. 7:1997;363-366.
84. Grasela T.H. Pharmacoepidemiology a scientific basis for outcomes research . Ann Pharmacother. 30:1996;188-190.
85. Watkins H., Rosenzweig A., Hwang D.S., et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 326:1992;1108-1114.
86. Thierfelder L., Watkins H., MacRae C., et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy a disease of the sarcomere . Cell. 77:1994;701-712.
87. Watkins H., Conner D., Thierfelder L., et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet. 11:1995;434-437.